Scarica l'app Stockscreener
301.52
0.83%
2.48
Dopo l'orario di chiusura:
301.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$299.04
Aprire:
$303.17
Volume 24 ore:
303.69K
Relative Volume:
0.99
Capitalizzazione di mercato:
$6.01B
Reddito:
$274.48M
Utile/perdita netta:
$153.56M
Rapporto P/E:
40.88
EPS:
7.3755
Flusso di cassa netto:
$114.06M
1 W Prestazione:
+6.36%
1M Prestazione:
+7.03%
6M Prestazione:
+47.40%
1 anno Prestazione:
+80.81%
Intervallo 1D:
$293.90
$305.35
Intervallo di 1 settimana:
$282.45
$305.35
Portata 52W:
$166.10
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
301.52 | 6.01B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Barclays Initiates Outperform on Ligand Pharmaceuticals (LGND) w - GuruFocus
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation - TradingView
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
LGND Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Begins Coverage on Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Barclays initiates Ligand Pharma stock with overweight rating By Investing.com - Investing.com South Africa
Barclays initiates Ligand Pharma stock with overweight rating - Investing.com
US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView
Ligand Pharmaceuticals Director Martine Zimmermann Reports RSU Tax Withholding on 115 Shares - Kalkine Media
Form 4 Ligand Pharmaceuticals Incorporated For: 24 September By Investing.com - Investing.com Canada
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies - TradingView
LGND Reiterated by HC Wainwright & Co. -- Price Target Maintained at $358 - GuruFocus
LGND Looks 60.8% Overvalued on GF Value™ - GuruFocus
Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal By Investing.com - Investing.com Canada
LGND Looks 60.6% Overvalued on GF Value™ - GuruFocus
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - marketscreener.com
Up to $47 million could help advance AvenCell's treatments for two blood cancers. - Stock Titan
Ligand and AvenCell Therapeutics Enter Financing Agreement - GlobeNewswire
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - McDermott Will & Schulte
LGND Maintained by Citigroup -- Price Target Raised to $397 - GuruFocus
Sydnexis sells Ryjunea EMEA royalty rights to Ligand for $23 million upfront - The Pharma Letter
Ligand Acquires Royalty Rights in Santen’s Ryjunea from Sydnexis for $23 Million - VisionMonday.com
LGND Looks 56.0% Overvalued on GF Value™ - GuruFocus
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - finance.yahoo.com
A production platform used in six approved biologics gets new funding. Primrose Bio will help expand its reach. - Stock Titan
Ligand Acquires Ryjunea Royalty Rights From Sydnexis for $23 Million - Minichart
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - finance.yahoo.com
Ligand Acquires Ryjunea EMEA Royalty Rights for $23M Upfront - TradingView
About 1 in 3 European children and teens may be nearsighted by 2050. Ligand buys rights to a children's eye drop. - Stock Titan
LGNZZ 8-K FilingsLIGAND PHARMS BETA CVR SEC 8-K - Stock Titan
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million - GlobeNewswire
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years - Benzinga
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha
Ligand Pharmaceuticals seen as a strong midcap pharma despite recent 10% drop, with promising royalty assets. - Pluang
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock - Investing.com
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):